MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from issuance of
common stock and...
$5,000,000
Sale of marketable
securities
$1,043,367
Net cash provided by
financing activities
$4,440,836
Net cash provided by
investing activities
$968,447
Canceled cashflow
$559,164
Canceled cashflow
$74,920
Net increase in cash
and cash...
$1,601,491
Canceled cashflow
$3,807,792
Payment of issuance
costs
$559,164
Stock-based compensation
$290,215
Depreciation and
amortization
$52,394
Accounts receivable
-$2,200
Purchase of marketable
securities
$74,920
Net cash used in
operating activities
-$3,807,792
Canceled cashflow
$344,809
Net loss
-$2,154,405
Change in fair value of
warrant liabilities
$1,220,121
Accounts payable
-$682,003
Accrued expenses and
other current...
-$64,070
Prepaid expenses and
other current assets
$25,938
Dividend and interest
income
$6,064
Back
Back
Cash Flow
BioRestorative Therapies, Inc. (BRTX)
BioRestorative Therapies, Inc. (BRTX)
source: myfinsight.com